Results 281 to 290 of about 9,152,470 (385)

Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2810-2821, May 2025.
Abstract Aims To understand real‐world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in the United States. Materials and Methods This retrospective, observational study used Optum's de‐identified Market Clarity database (index date: first‐observed tirzepatide claim ...
Emily R. Hankosky, Chanadda Chinthammit, Alexandra Meeks, Ahong Huang, Jennifer M. Ward, Donna Mojdami, Theresa Hunter Gibble   +6 more
wiley   +1 more source

Pneumatocele Development after Deceased-Donor Liver Transplantation for Multiple Hepatic Cysts due to Autosomal Dominant Polycystic Kidney Disease: A Case Report. [PDF]

Surg Case Rep
Yoshiyama A, Kawashima M, Nagata S, Fukushima T, Aze K, Cong Y, Nakao K, Nakao M, Toyokawa G, Konoeda C, Hasegawa K, Sato M.   +11 more
europepmc   +1 more source

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink, Dominique van Mil, Gozewijn D. Laverman, Hiddo J. L. Heerspink, Ron T. Gansevoort   +4 more
wiley   +1 more source

Wilson disease combined with polycystic ovary syndrome-clinical features, treatment, and outcome in Chinese patients. [PDF]

BMC Endocr Disord
Chen L, Fang MJ, Zhang LL, Liu YF, Han YZ, Yu XE, Xu Y.   +6 more
europepmc   +1 more source

Renal ammonia in autosomal dominant polycystic kidney disease

, 1994
Vicente E. Torres, Douglas S. Keith, Kenneth P. Offord, Sui Phin Kon, David M. Wilson   +4 more
openalex   +1 more source

Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease [PDF]

, 1996
Yoshihiko Kanno, Hiromichi Suzuki, Hirokazu Okada, Tsuneo Takenaka, T Saruta   +4 more
openalex   +1 more source

Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To describe temporal changes in the characteristics of medication‐initiator cohorts in persons with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods Adults with CKD and T2D initiating sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were identified in ...
Yuichiro Yano, Suguru Okami, Hiroshi Kanegae, Nikolaus G. Oberprieler, Catherine Johannes, Satoshi Yamashita, Kanae Yoshikawa‐Ryan, Csaba P. Kovesdy, David Vizcaya, Naoki Kashihara   +9 more
wiley   +1 more source

Association between lipid-lowering drug targets and the risk of cystic kidney disease: a drug-target Mendelian randomization analysis. [PDF]

Ren Fail
Lian Z, Liang Z, Chen Q, Xie C, Kong Y.
europepmc   +1 more source

Glucagon‐like peptide 1 (GLP‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The prevalence of diabetes and obesity continues to rise in women of reproductive age, with significant implications for both mother and foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments of diabetes and obesity. However, no Glucagon‐like peptide‐1 receptor agonists are currently approved for use during pregnancy ...
Claire H. Parker, Craig Slattery, Donal J. Brennan, Carel W. le Roux   +3 more
wiley   +1 more source

Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. [PDF]

J Clin Invest
Torres JA, Rezaei M, Broderick C, Lin L, Wang X, Hoppe B, Cowley BD, Savica V, Torres VE, Khan S, Holmes RP, Mrug M, Weimbs T.   +12 more
europepmc   +1 more source